Syed Shah, MD
Nephrology · Green Bay, WINPI 1447485784
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Amgen at 27.6% of the total. Reporting peaked in 2019 at $983 and has fallen 96.8% since, to $31 in 2025.
Across 85 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$538
- AstraZeneca$487
- Otsuka America Pharmaceutical, Inc.$368
- Vifor Pharma, Inc.$192
- Regeneron Healthcare Solutions, Inc.$113
- Akebia Therapeutics Inc$47
- plus $205 from 9 others
What the payments were for
- Food & beverage$1,78692%
- Education$1648%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $538 |
| AstraZeneca(2 entities) | 25 | $487 |
| Otsuka America Pharmaceutical, Inc. | 14 | $368 |
| Vifor Pharma, Inc. | 11 | $192 |
| Regeneron Healthcare Solutions, Inc. | 3 | $113 |
| Akebia Therapeutics Inc | 3 | $47 |
| Fresenius USA Marketing, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 2 | $30 |
| OPKO Pharmaceuticals, LLC | 2 | $28 |
| Amicus Therapeutics, Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,950 in reported general payments places this provider in the 75th percentile of 173 nephrology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcitriol | 564 | $9,799 |
| SpsSodium Polystyrene Sulfon/Sorb | 24 | $7,095 |
| Sevelamer Carbonate | 22 | $5,145 |
| RetacritEpoetin Alfa-Epbx | 12 | $1,567 |
| Cinacalcet Hcl | 15 | $853 |
| Losartan Potassium | 102 | $853 |
| Calcium Acetate | 15 | $729 |
| Nifedipine ErNifedipine | 24 | $628 |
| Lisinopril | 69 | $508 |
| Potassium Chloride | 23 | $489 |
| Furosemide | 91 | $485 |
| Valsartan | 29 | $462 |
| Hydralazine Hcl | 36 | $357 |
| Bumetanide | 24 | $327 |
| Amlodipine Besylate | 69 | $306 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Green Bay
- Kevin RegnerMilwaukee$246K
- Rosanna RanieriKenosha$84K
- Micah ChanFitchburg$80K
- Rishi KoraGlendale$57K
- Manohar AhujaMilwaukee$35K
- Ashraf El MeanawyMilwaukee$30K
- Anna GaddyMilwaukee$28K
- Sameer GuptaFond du Lac$20K
- Paul HannaMilwaukee$18K
- Fahad AzizFitchburg$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.